The 4th Annual Cell Engager Summit returns to bring you the latest on effectively targeting lymphocyte-restricted tumor-associated antigens to treat hematological malignancies, including CD19, CD20, BCMA, CD33, and CD123.
This must-attend meeting will provide a comprehensive understanding of the development of multi-specific cell engaging therapeutics in liquid and solid tumor indications, with the goal of bringing early-stage innovation to the clinic.
Learn all there is to know about the immune cell engager landscape, including clinical achievements, potential response predictors, and novel immune cell-based engager therapeutic discoveries.
You will leave this meeting with key steps to improving safety and efficacy in the solid tumor microenvironment through lower CRS, greater dose, and lower TMDD by targeting tumor antigens such as HER2 and EGFR, and modifying co-stimulatory receptors (for example CD137/4-1BB, CD28).
Ensure your Cell Engager program reaches full clinical potential through learning from the pioneers of immunotherapy.
Event name: 4th Cell Engager Therapeutics Summit
Event venue: Boston Park Plaza, 50 Park Plaza, Boston. MA 02116
Event website: https://ter.li/m3aamy
Event organiser: Hanson Wade
Phone number: (+1) 617 455 4188